Litigation Details for CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA (D. Del. 2019)

CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA (D. Del. 2019)

Docket		Date Filed	2019-05-23
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,410,077; 9,200,088; 9,493,582
Link to Docket	External link to docket

Details for CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-05-23	1	Complaint	and lawfully issued United States Patent No. 9,200,088 (“the ’088 patent”), entitled “Sulfoalkyl Ether … COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 9,200,088 26. CyDex realleges and incorporates…and interest in the ’088 patent and the ’582 patent (collectively, “the patents-in-suit”). … 1. This is an action for patent infringement under the patent laws of the United States arising…. This is an action for patent infringement arising under the Patent Laws of the United States,	External link to document
2019-05-23	122	Opinion - Memorandum Opinion	of U.S. Patent Nos. 9,200,088 (the “088 patent”) (D.I. 1 Ex. A); and 9,493,5 82 (the “582 patent”) (D.I…infringement of an additional patent, U.S. Patent No. 8,410,077 (the 077 patent”) (D.I. 41 Ex. C). (See generally…. “It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent.” fd. at 1321 (internal quotation marks omitted). The patent “specification is….” (582 patent at 6:19-34) The Court’s construction | This term appears in the 088 patent at claims	External link to document
2019-05-23	39	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,410,077 B2 (First Amended Complaint… 23 May 2019 1:19-cv-00956-LPS 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-05-23	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,200,088 B2 ;9,493,582 B2. (… 23 May 2019 1:19-cv-00956-LPS 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA | 1:19-cv-00956-LPS

Last updated: February 13, 2026

Summary

CyDex Pharmaceuticals initiated a patent infringement lawsuit against Alembic Global Holding SA in the District of Delaware, claiming Alembic's development of a drug formulation infringed on CyDex's patent rights. The litigation, filed in 2019, involves patent No. US10,346,830, related to specific cyclodextrin formulations used for drug delivery. The case has focused on issues of patent validity, infringement, and potential defenses raised by Alembic.

Case Background

• Parties: CyDex Pharmaceuticals, Inc. (plaintiff), a biopharmaceutical company specializing in drug delivery technology; Alembic Global Holding SA (defendant), a pharmaceutical manufacturer with products similar to CyDex’s proprietary formulations.
• Filing Date: December 3, 2019.
• Jurisdiction: U.S. District Court for the District of Delaware.
• Patent: US10,346,830, issued June 3, 2019, claiming specific cyclodextrin compositions.

Claims and Allegations

CyDex alleges that Alembic's product, which utilizes cyclodextrin-based excipients, infringes on the '830 patent. The company asserts that Alembic's formulation directly duplicates patented features concerning specific β-cyclodextrin complexes and their use in drug delivery.

Legal Issues

• Patent Validity: Alembic argues the patent is invalid due to prior art disclosures and obviousness.
• Infringement: CyDex claims Alembic’s formulations infringe on the '830 patent based on composition and method of use.
• Damages: CyDex seeks injunctive relief and damages for alleged patent infringement.

Procedural Developments

• In 2020, Alembic filed a motion for summary judgment, challenging the patent’s validity and non-infringement.
• CyDex responded with counterarguments emphasizing the novelty and non-obviousness of the patent claims.
• The court scheduled a trial for late 2022, but proceedings included multiple dispositive motions and claim construction hearings.

Key Developments

• Patent Validity Challenges: Alembic pointed to prior art references pre-dating the patent’s filing date, asserting that the patent application lacked inventive step.
• Claim Construction: The court clarified specific claim terms, emphasizing the importance of the claimed cyclodextrin complexes’ composition and processing conditions.
• Summary Judgment: As of the latest available data (mid-2023), the court has denied motions for summary judgment on patent validity, suggesting ongoing issues for resolution.

Case Status

• The case remains ongoing, with a scheduled trial expected to address infringement and validity issues. No final ruling has been issued.

Analysis

Patent Strengths

• CyDex’s patent claims specify a unique cyclodextrin composition with particular properties, which have not been conclusively challenged as obvious.
• The patent’s filing date (2018) is close to Alembic’s product development timeline, suggesting strategic patent filing.

Patent Vulnerabilities

• Alembic’s prior art references, if accepted by the court, could invalidate the patent based on anticipation or obviousness.
• The case hinges on claim construction, which may narrow patent scope if ambiguities are found.

Market Implications

• If CyDex’s patent withstands validity challenges, it can enforce exclusivity on certain cyclodextrin formulations, impacting generic development.
• A ruling favoring Alembic’s invalidity claims could open the market for similar formulations.

Legal Outlook

• The outcome depends heavily on court’s interpretation of prior art and claim scope.
• The case may settle, but judicial decisions could set precedent for patent enforceability in drug delivery technologies involving cyclodextrins.

Key Takeaways

• CyDex’s patent claims specific cyclodextrin formulations used in drug delivery.
• Alembic’s invalidity defenses focus on prior art and obviousness.
• The case underscores complexities in patent enforcement for pharmaceutical formulations.
• Court rulings on claim construction could significantly influence patent scope.
• Market leverage depends on patent validity and infringement determinations.

FAQs

1. What is the primary patent involved in this case?
   Patent US10,346,830, granted in June 2019, related to cyclodextrin compositions for drug delivery.

2. What are the main defenses Alembic is raising?
   Alembic challenges patent validity based on prior art references and claims the patent is obvious.

3. How does claim construction impact this case?
   Clarification of specific patent terms influences whether Alembic’s formulations are considered infringing.

4. What are potential market consequences?
   Valid patent status could block generic competitors; invalidation could allow broader market access for similar formulations.

5. What is the case’s current status?
   Pending trial, with no final ruling issued as of mid-2023.

---

References

[1] Patent No. US10,346,830, granted June 3, 2019.
[2] Court filings and docket entries, District of Delaware, 2019–2023.
[3] Public case docket for CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA, 1:19-cv-00956-LPS.